CN1274243C - 生发氨基酸及其制备方法 - Google Patents
生发氨基酸及其制备方法 Download PDFInfo
- Publication number
- CN1274243C CN1274243C CNB2004100103606A CN200410010360A CN1274243C CN 1274243 C CN1274243 C CN 1274243C CN B2004100103606 A CNB2004100103606 A CN B2004100103606A CN 200410010360 A CN200410010360 A CN 200410010360A CN 1274243 C CN1274243 C CN 1274243C
- Authority
- CN
- China
- Prior art keywords
- amino acid
- capsule
- hair tonic
- final product
- hair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 23
- 230000001256 tonic effect Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims description 5
- 229940024606 amino acid Drugs 0.000 claims abstract description 22
- 235000001014 amino acid Nutrition 0.000 claims abstract description 22
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 20
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 19
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 18
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract description 18
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 18
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 15
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 12
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 11
- 235000006109 methionine Nutrition 0.000 claims abstract description 11
- 229930182817 methionine Natural products 0.000 claims abstract description 11
- 229960004295 valine Drugs 0.000 claims abstract description 11
- 239000004470 DL Methionine Substances 0.000 claims abstract description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 10
- 229930064664 L-arginine Natural products 0.000 claims abstract description 10
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 10
- 239000004473 Threonine Substances 0.000 claims abstract description 10
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960001153 serine Drugs 0.000 claims abstract description 10
- 229960002898 threonine Drugs 0.000 claims abstract description 10
- 235000020958 biotin Nutrition 0.000 claims abstract description 9
- 239000011616 biotin Substances 0.000 claims abstract description 9
- 229960002685 biotin Drugs 0.000 claims abstract description 9
- 239000004395 L-leucine Substances 0.000 claims abstract description 8
- 235000019454 L-leucine Nutrition 0.000 claims abstract description 8
- 229960003136 leucine Drugs 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- 229960004441 tyrosine Drugs 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims description 18
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 15
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 12
- 239000012467 final product Substances 0.000 claims description 12
- 238000011049 filling Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229920000742 Cotton Polymers 0.000 claims description 6
- 235000019766 L-Lysine Nutrition 0.000 claims description 6
- 235000013878 L-cysteine Nutrition 0.000 claims description 6
- 239000004201 L-cysteine Substances 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 238000005498 polishing Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000011435 rock Substances 0.000 claims description 6
- 239000011265 semifinished product Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 238000002203 pretreatment Methods 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 9
- 201000004384 Alopecia Diseases 0.000 abstract description 7
- 231100000360 alopecia Toxicity 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000003648 hair appearance Effects 0.000 abstract description 4
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 abstract description 2
- 239000002574 poison Substances 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 abstract 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 14
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 7
- 235000020776 essential amino acid Nutrition 0.000 description 7
- 239000003797 essential amino acid Substances 0.000 description 7
- 229940055726 pantothenic acid Drugs 0.000 description 7
- 235000019161 pantothenic acid Nutrition 0.000 description 7
- 239000011713 pantothenic acid Substances 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 4
- 230000003779 hair growth Effects 0.000 description 4
- 239000004471 Glycine Chemical class 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000008935 nutritious Nutrition 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000027219 Deficiency disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000008852 Hyperoxaluria Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明为食品保健技术领域公开了一种生发的氨基酸及其制备方法,其主要特点是以生物素、DL-蛋氨酸、L-半胱氨酸、L-酪氨酸、L-精氨酸、L-苏氨酸、L-甘氨酸、L-缬氨酸、L-亮氨酸、L-赖氨酸、L-丝氨酸、泛酸钙经粉碎混合制成。该种氨基酸,可作为一种食品,人们长期服用后有促使毛发生长之功效,无毒副作用,从而从根本上治疗脱发和改变发质。
Description
技术领域:
本发明属于食品保健技术领域,具体涉及一种生发氨基酸及其制备方法。
背景技术:
随着人们工作,生活节奏的加快,及使用电脑的频率增高,加之膳食结构的简单、单一化,导致了脱发、发质变差的普遍现象,并且脱发的现象趋于年轻化,而现有的生发、治脱发的手段,多采用生发油外用涂抹,按摩,使头部血液循环加快,加之生发油的作用,用于生发。但是由于该种治疗方法是表面,只能治表,不能治本,且效果并不明显,由于按摩需用大量时间,并不能被人们所接受。
发明内容:
本发明的目的是研制一种从根本上治脱发、服用后可生发的组合物及其制备方法。
为达上述目的,本发明选用生物素、DL-蛋氨酸、L-半胱氨酸、L-酪氨酸、L-精氨酸、L-苏氨酸、L-甘氨酸、L-缬氨酸、L-亮氨酸、L-赖氨酸、L-丝氨酸、泛酸钙,经粉碎混合制成。该生发氨基酸是由下列组份制成的:(用量为重量份)生物素10-40,DL-蛋氨酸30-100,L-半胱氨酸5-25,L-酪氨酸10-45,L-精氨酸8-32,L-苏氨酸6-15,L-甘氨酸4-18,L-缬氨酸5-20,L-亮氨酸3-13,L-赖氨酸5-22,L-丝氨酸0.5-5,泛酸钙5-40。
制备本发明生发氨基酸的配方优选(重量份)配比范围是:
生物素15-35,DL-蛋氨酸40-90,L-半胱氨酸10-22,L-酪氨酸15-40,L-精氨酸10-30,L-苏氨酸8-12,L-甘氨酸6-15,L-缬氨酸8-18,L-亮氨酸5-12,L-赖氨酸8-20,L-丝氨酸0.8-4,泛酸钙10-30。
其制备工艺为:
a、原料前处理:按配比分取处方用各物质置粉碎机内粉碎,过60目即可,备用。
b、混合:依处方剂量准确称取粉碎后各物质置HC-200槽形混合机内,以等量递增配研法使混合均匀,取出,备用。
c、填充:取b项制成的混合物置胶囊填充机内,装入“0”号胶囊壳内,即可。
d、打光:取填充后的胶囊粒置棉纱布中,左右摇动,至胶囊粒外表面无粘附粉末为度,然后加入液体石蜡,左右摇动棉纱布,至使表面明亮光洁,无可见外来杂质,即可。
e、压板:将打光后的胶囊粒置DPH-140滚板组合式泡罩包装机内,热封,切割成胶囊板半成品,即可。
f、包装:将质检合格的半成品,依装量规格要求分装包装即为成品。
本发明的一个重要特点是氨基酸中含有丰富的营养成分,由于其中L-赖氨酸为碱性必需氨基酸,可以调节人体代谢平衡,为合成肉碱提供结构组分,刺激胃蛋白酶与胃酸的分泌,提高胃液分泌功能,增进食欲,促进生长和发育。DL-蛋氨酸为含硫必需氨基酸,可转化为腺苷甲硫氨酸,为机体内合成反应提供甲基,对有毒物或药物进行甲基化起解毒作用。L-苏氨酸是必需氨基酸,参与脂肪代谢。L-亮氨酸营养补充剂,是必需氨基酸。L-缬氨酸属支链氨基酸,也是必需氨基酸,当缬氨酸不足时,中枢神经系统功能发生紊乱,共济失调面出现四肢震颤。L-半胱氨酸是含硫的必需氨基酸,可降低人体对蛋氨酸的需要量,可缓解有毒物或有毒药物的中毒程度,其衍生物N-乙酰-L-半胱氨酸,由于巯基的作用,具有降低粘度的效果,此外,半胱氨酸能促进毛发的生长,可用于治疗秃发症。L-甘氨酸,甘氨酸与嘌呤、卟啉类、肌酸、乙醛酸的合成,乙醛酸因氧化产生草酸而促使遗传病草酸尿的发生,甘氨酸还可与种类繁多的物质结合,使之由胆汁或尿中排出,甘氨酸可提供非必需氨基酸氨源,改进氨基酸注射液在体内的耐受性。L-丝氨酸是合成嘌呤、胸腺嘧啶、胆碱的前体。本品含有促进人体毛发生长所需蛋白质的合成所需氨基酸,能维持营养不良患者的正氮平衡,用于各种原因引起进食差或需要特殊高能量及氨基酸的患者得到合理营养,促进机体康复。泛酸钙,泛酸作为辅酶A的重要组成成分,在碳水化合物、脂肪和蛋白质代谢的酰基转移过程中,起着重要的作用。泛酸具有旋光性,但只有它的右旋异构体才具有生理活性。天然的泛酸均为其右旋异构体,而常用的人工合成的泛酸为其钙盐,是右旋或消旋化合物。消旋泛酸的作用仅为右旋泛酸的一半。泛酸钙是一种白色、无臭、微苦的粉状结晶,溶于水,对光、氧化剂和还原剂都比较稳定,但在PH5-7的水溶液中遇热易受破坏。大多数营养补充剂均使用泛酸钙。营养不足引起的缺乏症,很可能是多种营养素共同不足引起的,其中可能存在着泛酸的不足或缺乏。在多种维生素缺乏时,往往可以看到血中泛酸水平降低,但由于同时存在多种缺乏症,常难以区分每一种因素所引起的特殊症状。L-酪氨酸是营养补充剂。L-精氨酸是一种双基氨基酸,对成人来说虽然不是必需氨基酸,但在有些情况如机体发育不成熟或在严重应激条件下,如果缺乏精氨酸,机体便不能维持正常平衡与生理功能。精氨酸的免疫调节功能,可防止胸腺的退化,补充精氨酸能增加胸腺的重量,促进胸腺中淋巴细胞的生长,对恢复肠绒毛,提高免疫功能,有显著功效。
以上各种物质携同作用,合成了对人体特别是对毛发非常有益的氨基酸。因毛发重量的95%是胶质蛋白,而胶质蛋白是由17种氨基酸组成的,其中8种氨基酸是人体必需的,9种氨基酸是人体非必需的,起着辅助作用。因此17种氨基酸决定了毛发的质量,而该种混合成的氨基酸经药理试验,含有丰富的促使毛发生长的氨基酸,人们服用后均有促使毛发生长之功效。作为一种食品,可长期服用,而不会对人体产生副作用。具有可促使毛发生长,改变发质,从根本上治脱发等显著优点。
具体实施方案:
结合附图及实例对本发明做进一步说明。
图1为本发明的工艺流程简图。
实施例1:按下述配比称取原料(克)生物素10,DL-蛋氨酸100,L-半胱氨酸5,L-酪氨酸10,L-精氨酸8,L-苏氨酸6,L-甘氨酸4,L-缬氨酸5,L-亮氨酸13,L-赖氨酸5,L-丝氨酸0.5,泛酸钙5。
实施例2:按下述配比称取原料(克)生物素40,DL-蛋氨酸30,L-半胱氨酸25,L-酪氨酸35,L-精氨酸32,L-苏氨酸15,L-甘氨酸15,L-缬氨酸20,L-亮氨酸3,L-赖氨酸15,L-丝氨酸3,泛酸钙30。
实施例3:按下述配比称取原料(克)生物素30,DL-蛋氨酸60,L-半胱氨酸20,L-酪氨酸45,L-精氨酸30,L-苏氨酸12,L-甘氨酸18,L-缬氨酸15,L-亮氨酸10,L-赖氨酸22,L-丝氨酸5,泛酸钙40。
其生产方法如下:a、原料前处理:按配比分取处方用各物质置粉碎机内粉碎,过60目即可,备用。
b、混合:依处方剂量准确称取粉碎后各物质置HC-200槽形混合机内,以等量递增配研法使混合均匀,取出,备用。
c、填充:取b项制成的混合物置胶囊填充机内,装入“0”号胶囊壳内,即可。
d、打光:取填充后的胶囊粒置棉纱布中,左右摇动,至止胶囊粒外表面无粘附粉末为度,然后加入液体石蜡,左右摇动棉纱布,至使表面明亮光洁,无可见外来杂质,即可。
e、压板:将打光后的胶囊粒置DPH-140滚板组合式泡罩包装机内,热封,切割成胶囊板半成品,即可。
f、包装:将质检合格的半成品,依装量规格要求分装包装即为成品。
附:河南省疾病预防控制中心检测报告
Claims (3)
1、一种生发氨基酸,其特征在于它是由下述重量配比的物质制成的,生物素10-40,DL-蛋氨酸30-100,L-半胱氨酸5-25,L-酪氨酸1045,L-精氨酸8-32,L-苏氨酸6-15,L-甘氨酸4-18,L-缬氨酸5-20,L-亮氨酸3-13,L-赖氨酸5-22,L-丝氨酸0.5-5,泛酸钙5-40。
2、根据权利要求1所述的一种生发氨基酸,其特征是各物质的重量配比是:生物素15-35,DL-蛋氨酸40-90,L-半胱氨酸10-22,L-酪氨酸15-40,L-精氨酸10-30,L-苏氨酸8-12,L-甘氨酸6-15,L-缬氨酸8-18,L-亮氨酸5-12,L-赖氨酸8-20,L-丝氨酸0.8-4,泛酸钙10-30。
3、根据权利要求1所述的一种生发氨基酸的制备方法,其特征在于:
a、原料前处理:按配比分取处方用各物质置粉碎机内粉碎,过60目即可,备用;
b、混合:依处方剂量准确称取粉碎后各成分置HC-200槽形混合机内,以等量递增配研法使混合均匀,取出,备用;
c、填充:取b项制成的混合物置胶囊填充机内,装入“0”号胶囊壳内,即可;
d、打光:取填充后的胶囊粒置棉纱布中,左右摇动,至胶囊粒外表面无粘附粉末为度,然后加入液体石蜡,左右摇动棉纱布,至使表面明亮光洁,无可见外来杂质,即可;
e、压板:将打光后的胶囊粒置DPH-140滚板组合式泡罩包装机内,热封,切割成胶囊板半成品,即可;
f、包装:将质检合格的半成品,依装量规格要求分装包装即为成品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100103606A CN1274243C (zh) | 2004-06-22 | 2004-06-22 | 生发氨基酸及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100103606A CN1274243C (zh) | 2004-06-22 | 2004-06-22 | 生发氨基酸及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1593217A CN1593217A (zh) | 2005-03-16 |
| CN1274243C true CN1274243C (zh) | 2006-09-13 |
Family
ID=34662610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100103606A Expired - Fee Related CN1274243C (zh) | 2004-06-22 | 2004-06-22 | 生发氨基酸及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1274243C (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5315992B2 (ja) * | 2006-06-08 | 2013-10-16 | 味の素株式会社 | 育毛用組成物 |
| ES2436246B2 (es) * | 2013-09-06 | 2014-04-28 | Cnce Innovacion, S.L. | Composición cosmética para el cuidado y tratamiento de la alopecia |
| CN106727167A (zh) * | 2017-03-14 | 2017-05-31 | 佛山文森特知识产权服务有限公司 | 一种生姜育发组合物及其制备方法 |
-
2004
- 2004-06-22 CN CNB2004100103606A patent/CN1274243C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1593217A (zh) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108967800A (zh) | 一种功能性固体饮料及其制备方法 | |
| MX2015005649A (es) | Hidrolizado de colageno y uso del mismo. | |
| CN1323165A (zh) | 缓慢消化的蛋白质及其用途 | |
| WO2006034586A1 (en) | Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker | |
| JP6441825B2 (ja) | フィラーの効能維持用組成物 | |
| Li et al. | Dietary starch sources affect net portal appearance of amino acids and glucose in growing pigs | |
| CN108703249A (zh) | 一种胶原蛋白产品及其制备方法 | |
| KR19990035872A (ko) | 체지방률을 낮추고 체조성을 개선시키는 식품 조성물 및 체지방률을 낮추고 체조성을 개선시키는 방법 | |
| CN105595338A (zh) | 一种适用于糖尿病的特殊医学用途配方食品及其制备方法 | |
| CA2514687A1 (en) | Advenced vitamin c-based composition with enhanced biotransformation and utilization of protein and l-carnitine for nutritional supplementation or the like | |
| CN1274243C (zh) | 生发氨基酸及其制备方法 | |
| CN115702687A (zh) | 一种胶原蛋白肽透明质酸钠氨基酸组合物的制备与应用 | |
| JP2007500208A (ja) | 慢性創傷の治療方法又は予防方法並びにそれに使用するためのグリシン及び/又はロイシンを含む完全栄養組成物 | |
| CN102342407A (zh) | 一种抗疲劳饮料及其制备方法 | |
| KR20230135205A (ko) | 류신 및 시트룰린 성분을 포함하는 근손실 예방, 개선용 조성물 | |
| DE68910126T2 (de) | Nahrungsmittelzusammensetzung. | |
| Davidova et al. | Pharmacological activity of amino acids and prospects for the creation of drugs based on them | |
| CN108541912A (zh) | 一种抗氧化降血脂组合物及其制备方法和应用 | |
| CN114365850A (zh) | 一种具有改善软骨健康的多肽组合物及其制备方法 | |
| JP2007197363A (ja) | 栄養補助剤 | |
| CN110584120A (zh) | 骨健康组合物 | |
| RU2552444C1 (ru) | Композиция продукта с биологически активными свойствами | |
| CN109464651A (zh) | 一种软骨代谢异常疾病改善用健康食品及药品组合物 | |
| JP2011223965A (ja) | コラーゲンを含む食品化合物 | |
| CN102823778A (zh) | 一种实验小型猪专用功能性饲料添加剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060913 Termination date: 20140622 |
|
| EXPY | Termination of patent right or utility model |